This page contains exclusive content for the member of the following sections: TTS. Log in to view.
Presenter: Roberto, Marcén, Madrid, Spain
Authors: Marcén R., Jimenez-Alvaro S., Villacorta F., Fernández-Rodriguez A., Galeano C., Villafruela J., Teruel J., Burgos F., Quereda C.
KIDNEY - CHRONIC GRAFT INJURY
R. Marcén, S. Jimenez-alvaro, F.J. Villacorta, A. Fernández-rodriguez, C. Galeano, J.J. Villafruela, J.L. Teruel, F.J. Burgos, C. Quereda
Nephrology, Hospital Ramón y Cajal, Madrid/SPAIN
Body: Introduction: Persistent hyperparathyroidism has been previously reported after renal transplantation. However, most of these studies are cross-sectional or have a short follow-up. Deficiency of vitamin D is also common in renal transplant recipients but there are few studies about the natural evolution of this disorder. The aims of the present study was to prospectively evaluate the calcium-phosphate metabolism parameters during 3 years after transplantation. Patients and methods: 182 renal transplant recipients with a functioning graft at 12 months were included in the study. Donor and recipient-related data at the time of transplantation as well as graft function and calcium-phosphate metabolism parameters including; serum calcium and phosphate, intact parathyroid hormone (iPTH), calcidiol (25OHD), calcitriol (1,25OHD) and tubular reabsorption of phosphorus (TRP) at 1,3,6,12,24 and 36 months were prospectively collected. Results: Data at 3, 12 and 36 months are expressed at the table 1:
Variable | 3 months | 12 months | 36 months |
Creatinine (mg/dL) | 1.7±0.6 | 1.6±0.6 | 1.6±0.5 |
Calcium (mg/dL) | 9.3±0.9 | 9.5±0.7 | 9.4±1.0 |
Calcium>10.2g/dL | 10.2% | 15.2% | 12.8% |
Phosphate (mg/dL) | 2.8±0.5 | 3.0±0.6*** | 3.1±0.7*** |
iPTH (pg/mL) | 180±189 | 166±134* | 152±131** |
iPTH >150 pg/mL | 43.2% | 40.0% | 24.7% |
25OHD (ng/ml) | 24.2±14.6 | 22.3±13.0 | 20.5±10.5* |
25OHD<16 ng/mL | 32.6% | 34.0% | 43.5% |
1,25OHD (pg/mL) | 28.6±28.4 | 31.8±21.9 | 40.8±27.2** |
1,25OHD<20pg/mL | 49.5% | 36.8% | 31.3% |
Disclosure: All authors have declared no conflicts of interest.
By viewing the material on this site you understand and accept that:
The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada